Aerie Pharmaceuticals Inc. Common Stock (NASDAQ:AERI)

Home >> Stock >> Aerie Pharmaceuticals Inc. Common Stock >> Metrics

Aerie Pharmaceuticals is a commercial-stage company focused on the development and commercialization of eye disease therapies including glaucoma and other eye-diseases.'In 2017, Aerie received FDA approval for its lead drug, Rhopressa, for the lowering of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Rhopressa is a once-daily formulation for IOP in patients suffering from open-angle glaucoma and ocular hypertension. The FDA also approved Rocklatan, a once-daily, quadruple action fixed-dose combination of Rhopressa and Xalatan. Glaucoma is one of the largest segments in the global ophthalmic market.'In addition, the company is developing sustained-release implants focused on retinal indications. These include AR-13503 (Rho kinase and Protein kinase C inhibitor implant) for macular edema due to retinal vein occlusion(RVO) and AR-1105 (dexamethasone steroid implant) for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).'...

+See More

Blog+More

Mitch Anthony explains why it is important for sales leaders to apply sound social skills and emotional competences to fulfill customer needs, wants, demands, desires, and other preferences.

Jonah Whanau

2025-07-12 11:35:00 Saturday ET

Mitch Anthony explains why it is important for sales leaders to apply sound social skills and emotional competences to fulfill customer needs, wants, demands, desires, and other preferences.

Mitch Anthony explains why it is now more important for top sales leaders to apply social skills and emotional competences to fulfill customer needs, wants,

+See More

AYA fintech finbuzz illustrative video tutorials on YouTube

Amy Hamilton

2019-05-05 10:46:10 Sunday ET

AYA fintech finbuzz illustrative video tutorials on YouTube

This video collection shows the major features of our AYA fintech network platform for stock market investors: (1) AYA stock market content curation;&nbs

+See More

The U.S. federal government debt has risen from less than 40% of total GDP about a decade ago to 78% as of May 2018.

John Fourier

2018-06-01 07:30:00 Friday ET

The U.S. federal government debt has risen from less than 40% of total GDP about a decade ago to 78% as of May 2018.

The U.S. federal government debt has risen from less than 40% of total GDP about a decade ago to 78% as of May 2018. The Congressional Budget Office predict

+See More

Response to USPTO fintech patent protection and accreditation

Andy Yeh Alpha

2023-01-09 10:31:00 Monday ET

Response to USPTO fintech patent protection and accreditation

Response to USPTO fintech patent protection As of early-January 2023, the U.S. Patent and Trademark Office (USPTO) has approved our U.S. utility patent

+See More

OraSure and its subsidiary DNA Genotek specialize in the lean production of home DNA spit tubes.

Monica McNeil

2019-04-01 08:28:00 Monday ET

OraSure and its subsidiary DNA Genotek specialize in the lean production of home DNA spit tubes.

OraSure and its subsidiary DNA Genotek specialize in the lean production of home DNA spit tubes. OraSure extracts core genetic information from microbiome s

+See More

San Francisco Fed CEO Mary Daly suggests that trade escalation is not the only risk in the global economy.

Rose Prince

2019-06-19 09:27:00 Wednesday ET

San Francisco Fed CEO Mary Daly suggests that trade escalation is not the only risk in the global economy.

San Francisco Fed CEO Mary Daly suggests that trade escalation is not the only risk in the global economy. Due to the current Sino-U.S. trade tension, the g

+See More